Acute Lung Injury - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Acute Lung Injury - Pipeline Review, H1 2016', provides an overview of the Acute Lung Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Lung Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Lung Injury - The report reviews pipeline therapeutics for Acute Lung Injury by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Acute Lung Injury therapeutics and enlists all their major and minor projects - The report assesses Acute Lung Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Acute Lung Injury Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Acute Lung Injury - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Acute Lung Injury Overview 11 Therapeutics Development 12 Pipeline Products for Acute Lung Injury - Overview 12 Pipeline Products for Acute Lung Injury - Comparative Analysis 13 Acute Lung Injury - Therapeutics under Development by Companies 14 Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes 17 Acute Lung Injury - Pipeline Products Glance 18 Clinical Stage Products 18 Early Stage Products 19 Acute Lung Injury - Products under Development by Companies 20 Acute Lung Injury - Products under Investigation by Universities/Institutes 22 Acute Lung Injury - Companies Involved in Therapeutics Development 23 Altor BioScience Corporation 23 Apeptico Forschung und Entwicklung GmbH 24 Commence Bio, Inc. 25 CompleGen, Inc. 26 FirstString Research, Inc. 27 GlaxoSmithKline Plc 28 Histocell S.L. 29 Navigen Pharmaceuticals, Inc. 30 Noxxon Pharma AG 31 Quark Pharmaceuticals, Inc. 32 S-Evans Biosciences, Inc. 33 Silence Therapeutics Plc 34 Stemedica Cell Technologies, Inc. 35 Windtree Therapeutics, Inc. 36 Acute Lung Injury - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Target 38 Assessment by Mechanism of Action 40 Assessment by Route of Administration 42 Assessment by Molecule Type 44 Drug Profiles 46 ALT-836 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Atu-111 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 BC-1215 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 BIO-10901 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 CGX-1037 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 CMB-200 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 FAB-117-HC - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 GSK-2586881 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 GSK-2862277 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 L-Citrulline - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 LTI-02 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 lucinactant - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 MG-53 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 NAV-2729 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 NOXD-19 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 P- BEFizumab - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 Peptide to Activate PAI-1 for Acute Lung Injury - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 QPLI-2 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 R-10001 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 R-107 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 R-901 - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 R-911 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 S-1229 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 solnatide - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 Stem Cell Therapy for Acute Lung Injury - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 Stem Cell Therapy for Acute Lung Injury - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure and Neurodegenerative Diseases - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 Synthetic Peptides for Respiratory Distress Syndrome and Acute Lung Injury - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 TXA-302 - Drug Profile 103 Product Description 103 Mechanism Of Action 103 R&D Progress 103 Acute Lung Injury - Dormant Projects 104 Acute Lung Injury - Discontinued Products 106 Acute Lung Injury - Product Development Milestones 107 Featured News & Press Releases 107 Jul 30, 2015: Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 107 Aug 05, 2014: Silence Therapeutics Announces Publication of pre-clinical study data on use of Atu111 RNAi in sepsis 107 Oct 08, 2013: Discovery Labs Announces Notice of Allowance for a U.S. Patent Supporting the AEROSURF Development Program 108 Sep 27, 2012: Discovery Labs Initiates Research Projects With Research Institutions And US Government Agencies To Assess KL(4) Surfactant Utility In Acute Lung Injury 108 Sep 10, 2012: Silence Therapeutics' Proof of Concept Study In Preclinical Model Shows Survival Benefit With Atu111 In Combination With Antibiotics 109 Dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase IIa Study In Acute Lung Injury Patients 110 May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 110 Apr 20, 2011: Discovery Labs's KL4 Surfactant Aerosolization Program Data To Be Presented At Pediatric Academic Societies Annual Meeting 111 Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 111 Appendix 113 Methodology 113 Coverage 113 Secondary Research 113 Primary Research 113 Expert Panel Validation 113 Contact Us 113 Disclaimer 114
List of Tables
Number of Products under Development for Acute Lung Injury, H1 2016 12 Number of Products under Development for Acute Lung Injury - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 15 Number of Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Development, H1 2016 19 Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 (Contd..1) 21 Products under Investigation by Universities/Institutes, H1 2016 22 Acute Lung Injury - Pipeline by Altor BioScience Corporation, H1 2016 23 Acute Lung Injury - Pipeline by Apeptico Forschung und Entwicklung GmbH, H1 2016 24 Acute Lung Injury - Pipeline by Commence Bio, Inc., H1 2016 25 Acute Lung Injury - Pipeline by CompleGen, Inc., H1 2016 26 Acute Lung Injury - Pipeline by FirstString Research, Inc., H1 2016 27 Acute Lung Injury - Pipeline by GlaxoSmithKline Plc, H1 2016 28 Acute Lung Injury - Pipeline by Histocell S.L., H1 2016 29 Acute Lung Injury - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 30 Acute Lung Injury - Pipeline by Noxxon Pharma AG, H1 2016 31 Acute Lung Injury - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 32 Acute Lung Injury - Pipeline by S-Evans Biosciences, Inc., H1 2016 33 Acute Lung Injury - Pipeline by Silence Therapeutics Plc, H1 2016 34 Acute Lung Injury - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 35 Acute Lung Injury - Pipeline by Windtree Therapeutics, Inc., H1 2016 36 Assessment by Monotherapy Products, H1 2016 37 Number of Products by Stage and Target, H1 2016 39 Number of Products by Stage and Mechanism of Action, H1 2016 41 Number of Products by Stage and Route of Administration, H1 2016 43 Number of Products by Stage and Molecule Type, H1 2016 45 Acute Lung Injury - Dormant Projects, H1 2016 104 Acute Lung Injury - Dormant Projects (Contd..1), H1 2016 105 Acute Lung Injury - Discontinued Products, H1 2016 106
List of Figures
Number of Products under Development for Acute Lung Injury, H1 2016 12 Number of Products under Development for Acute Lung Injury - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Products, H1 2016 19 Assessment by Monotherapy Products, H1 2016 37 Number of Products by Top 10 Targets, H1 2016 38 Number of Products by Stage and Top 10 Targets, H1 2016 38 Number of Products by Top 10 Mechanism of Actions, H1 2016 40 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 40 Number of Products by Routes of Administration, H1 2016 42 Number of Products by Stage and Routes of Administration, H1 2016 42 Number of Products by Top 10 Molecule Types, H1 2016 44 Number of Products by Stage and Top 10 Molecule Types, H1 2016 44
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. EvolvRead More...
Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers isRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.